L Santo

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. pmc AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition
    L Santo
    Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 29:2325-36. 2010
  2. doi request reprint Ascorbic acid inhibits antitumor activity of bortezomib in vivo
    G Perrone
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 23:1679-86. 2009
  3. pmc Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
    D Cirstea
    1 MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 2 Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Boston, MA, USA
    Leukemia 27:2366-75. 2013
  4. doi request reprint Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
    T Scullen
    Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Leukemia 27:1715-21. 2013
  5. doi request reprint A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
    S Vallet
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Leukemia 25:1174-81. 2011

Collaborators

  • K C Anderson
  • N C Munshi
  • Noopur Raje
  • Y Hu
  • M Cavo
  • M Ladetto
  • D Cirstea
  • S Vallet
  • T Hideshima
  • H Eda
  • N Nemani
  • T Scullen
  • K Patel
  • G Gorgun
  • G Perrone
  • A Yee
  • M Fulciniti
  • F Cottini
  • Y Mishima
  • R Suzuki
  • H Ohguchi
  • H Loferer
  • A Mahindra
  • N Mimura
  • D T Scadden
  • P Veiby
  • S Pozzi
  • M T Fulciniti
  • N Vaghela
  • E Calabrese
  • H Ikeda
  • Y Okawa
  • M Baccarani
  • D Chauhan

Detail Information

Publications5

  1. pmc AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition
    L Santo
    Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Oncogene 29:2325-36. 2010
    ..These results offer new insights into the crucial, yet controversial role of GSK-3beta in MM and show significant anti-MM activity of AT7519, providing the rationale for its clinical evaluation in MM...
  2. doi request reprint Ascorbic acid inhibits antitumor activity of bortezomib in vivo
    G Perrone
    Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Leukemia 23:1679-86. 2009
    ....
  3. pmc Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs
    D Cirstea
    1 MGH Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA 2 Leebow Institute of Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Disease Center, Dana Farber Cancer Institute, Boston, MA, USA
    Leukemia 27:2366-75. 2013
    ....
  4. doi request reprint Lenalidomide in combination with an activin A-neutralizing antibody: preclinical rationale for a novel anti-myeloma strategy
    T Scullen
    Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA
    Leukemia 27:1715-21. 2013
    ..This provides the rationale for an ongoing clinical trial (NCT01562405) combining lenalidomide with an anti-activin A strategy. ..
  5. doi request reprint A novel role for CCL3 (MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function
    S Vallet
    Division of Hematology and Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Leukemia 25:1174-81. 2011
    ..Our results show that CCL3, in addition to its known catabolic activity, reduces bone formation by inhibiting OB function, and therefore contributes to OB/OC uncoupling in MM...